{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:20:06Z","timestamp":1793467206695,"version":"4.5.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.lpm.2021.104080","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T21:04:56Z","timestamp":1634850296000},"page":"104080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Prolactinomas"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2692-4960","authenticated-orcid":false,"given":"Luiz Eduardo","family":"Wildemberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christhiane","family":"Fialho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9250-3558","authenticated-orcid":false,"given":"Monica R.","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2021.104080_bib0001","article-title":"Hypeprolactinemia: still an insidious diagnosis","author":"Aliberti","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.lpm.2021.104080_bib0002","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104080_bib0003","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11102-019-01009-y","article-title":"Prolactinomas in males: any differences?","volume":"23","author":"Duskin-Bitan","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2021.104080_bib0004","doi-asserted-by":"crossref","first-page":"236","DOI":"10.20945\/2359-3997000000032","article-title":"Controversial issues in the management of hyperprolactinemia and prolactinomas - an overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism","volume":"62","author":"Vilar","year":"2018","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104080_bib0005","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-014-0183-4","article-title":"Cabergoline treatment in acromegaly: cons","volume":"46","author":"Kasuki","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.lpm.2021.104080_bib0006","first-page":"105","article-title":"Surgery as a viable alternative first-line treatment for prolactinoma patients. a systematic review and meta-analysis","author":"Zamanipoor Najafabadi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104080_bib0007","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ecl.2007.10.013","article-title":"Hyperprolactinemia and prolactinomas","volume":"37","author":"Mancini","year":"2008","journal-title":"Endocrinol Metabol Clinics N Am"},{"key":"10.1016\/j.lpm.2021.104080_bib0008","first-page":"1167","volume":"18","author":"Buvat","year":"1983"},{"key":"10.1016\/j.lpm.2021.104080_bib0009","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1056\/NEJMcp025334","article-title":"Clinical practice. Prolactinoma","volume":"349","author":"Schlechte","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104080_bib0010","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0889-8529(05)70203-6","article-title":"Disorders of prolactin secretion","volume":"30","author":"Molitch","year":"2001","journal-title":"Endocrinol Metabol Clin N Am"},{"key":"10.1016\/j.lpm.2021.104080_bib0011","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/BF03346388","article-title":"Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients","volume":"31","author":"Vilar","year":"2008","journal-title":"J Endocrinolog Invest"},{"key":"10.1016\/j.lpm.2021.104080_bib0012","volume":"8","author":"Samperi","year":"2019","journal-title":"Hyperprolactinaemia"},{"key":"10.1016\/j.lpm.2021.104080_bib0013","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1530\/EJE-20-0058","article-title":"Central diabetes insipidus and pituitary stalk thickening in adults: distinction of neoplastic from non-neoplastic lesions","volume":"181","author":"Devuyst","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0014","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1590\/0004-2730000002961","article-title":"[Prolactinoma]","volume":"58","author":"Glezer","year":"2014","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.1016\/j.lpm.2021.104080_bib0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11102-019-01024-z","article-title":"Biochemical diagnosis in prolactinomas: some caveats","volume":"23","author":"Petersenn","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2021.104080_bib0016","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2265.2003.01694.x","article-title":"Hyperprolactinaemia in hypothyroidism: clinical significance and impact of TSH normalization","volume":"58","author":"Raber","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2021.104080_bib0017","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1507\/endocrj.K10E-215","article-title":"The prevalence of hyperprolactinaemia in overt and subclinical hypothyroidism","volume":"57","author":"Hekimsoy","year":"2010","journal-title":"Endocr J"},{"key":"10.1016\/j.lpm.2021.104080_bib0018","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000499694","article-title":"Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia","volume":"109","author":"Vilar","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.lpm.2021.104080_bib0019","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/hdi.12489","article-title":"Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis","volume":"21","author":"Lo","year":"2017","journal-title":"Hemodial Int"},{"key":"10.1016\/j.lpm.2021.104080_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8122203","article-title":"Hyperprolactinaemia","volume":"8","author":"Samperi","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.lpm.2021.104080_bib0021","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1055\/s-0034-1375612","article-title":"Serum prolactin in advanced chronic liver disease","volume":"46","author":"Ress","year":"2014","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.lpm.2021.104080_bib0022","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1210\/jc.2014-2623","article-title":"Ectopic prolactin secretion from a perivascular epithelioid cell tumor (PEComa)","volume":"99","author":"Korytnaya","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104080_bib0023","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa1307557","article-title":"Mutant prolactin receptor and familial hyperprolactinemia","volume":"369","author":"Newey","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104080_bib0024","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrendo.2015.36","article-title":"New insights in prolactin: pathological implications","volume":"11","author":"Bernard","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0025","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4065\/80.8.1050","article-title":"Medication-induced hyperprolactinemia","volume":"80","author":"Molitch","year":"2005","journal-title":"Mayo Clinic Procee"},{"key":"10.1016\/j.lpm.2021.104080_bib0026","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/jcp.0b013e31815ac4e5","article-title":"Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives","volume":"27","author":"Byerly","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.lpm.2021.104080_bib0027","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0028","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.beem.2009.05.003","article-title":"Pituitary tumours: the prolactinoma","volume":"23","author":"Colao","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.lpm.2021.104080_bib0029","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ecl.2020.04.002","article-title":"The epidemiology of pituitary adenomas","volume":"49","author":"Daly","year":"2020","journal-title":"Endocrinol Metab Clin N Am"},{"key":"10.1016\/j.lpm.2021.104080_bib0030","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/eje.0.1480325","article-title":"Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia","volume":"148","author":"Colao","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0031","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)","volume":"72","author":"Fernandez","year":"2010","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0032","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11102-019-00997-1","article-title":"Pathology of prolactinomas: any predictive value?","volume":"23","author":"Lopes","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2021.104080_bib0033","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","article-title":"Overview of the 2017 WHO classification of pituitary tumors","volume":"28","author":"Mete","year":"2017","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.lpm.2021.104080_bib0034","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/geronj\/35.1.16","article-title":"Pituitary adenomas in old age","volume":"35","author":"Kovacs","year":"1980","journal-title":"J Gerontol"},{"key":"10.1016\/j.lpm.2021.104080_bib0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/ageing\/18.4.247","article-title":"The presentation and management of pituitary tumours in the elderly","volume":"18","author":"Cohen","year":"1989","journal-title":"Age Ageing"},{"key":"10.1016\/j.lpm.2021.104080_bib0036","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1046\/j.1365-2265.1997.1180933.x","article-title":"Pituitary tumours presenting in the elderly: management and outcome","volume":"46","author":"Benbow","year":"1997","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0037","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/eje.0.1400383","article-title":"Pituitary tumours in the elderly: a 20 year experience","volume":"140","author":"Turner","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0038","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1530\/EJE-10-0519","article-title":"Pituitary adenomas in childhood, adolescence and young adulthood: presentation, management, endocrine and metabolic outcomes","volume":"163","author":"Steele","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0039","article-title":"Prolactinoma in Childhood and Adolescence - Tumour Size at Presentation Predicts Management Strategy: single centre series and a systematic review and meta-analysis","author":"Arya","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2021.104080_bib0040","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s40618-017-0725-8","article-title":"Frequency of familial pituitary adenoma syndromes among patients with functioning pituitary adenomas in a reference outpatient clinic","volume":"40","author":"Marques","year":"2017","journal-title":"J Endocrinolog Invest"},{"key":"10.1016\/j.lpm.2021.104080_bib0041","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1055\/a-1143-5930","article-title":"Clinical and molecular update on genetic causes of pituitary adenomas","volume":"52","author":"Vasilev","year":"2020","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.lpm.2021.104080_bib0042","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4065\/73.11.1046","article-title":"Prolactinomas in male and female patients: a comparative clinicopathologic study","volume":"73","author":"Calle-Rodrigue","year":"1998","journal-title":"Mayo Clinic proceedings"},{"key":"10.1016\/j.lpm.2021.104080_bib0043","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","article-title":"Guidelines for diagnosis and therapy of MEN type 1 and type 2","volume":"86","author":"Brandi","year":"2001","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.lpm.2021.104080_bib0044","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000345670","article-title":"Multiple endocrine neoplasia type 4","volume":"41","author":"Lee","year":"2013","journal-title":"Front Horm Res"},{"key":"10.1016\/j.lpm.2021.104080_bib0045","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1210\/jcem.86.9.7903","article-title":"Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation","volume":"86","author":"Stratakis","year":"2001","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.lpm.2021.104080_bib0046","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/humu.21292","article-title":"Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families","volume":"31","author":"Igreja","year":"2010","journal-title":"Hum Mutation"},{"key":"10.1016\/j.lpm.2021.104080_bib0047","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1530\/EC-17-0237","article-title":"mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation","volume":"6","author":"Araujo","year":"2017","journal-title":"Endocr Connect"},{"key":"10.1016\/j.lpm.2021.104080_bib0048","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1530\/EJE-15-1272","article-title":"Management of endocrine disease: pituitary 'incidentaloma': neuroradiological assessment and differential diagnosis","volume":"175","author":"Vasilev","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0049","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/B978-0-444-59602-4.00013-7","article-title":"Hyperprolactinemia and prolactinoma","volume":"124","author":"Romijn","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.lpm.2021.104080_bib0050","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.4158\/EP11341.CR","article-title":"Association of dengue hemorrhagic fever with multiple risk factors for pituitary apoplexy","volume":"18","author":"Wildemberg","year":"2012","journal-title":"Endocr Pract"},{"key":"10.1016\/j.lpm.2021.104080_bib0051","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-018-0870-x","article-title":"Apoplexy in nonfunctioning pituitary adenomas","volume":"21","author":"Wildemberg","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2021.104080_bib0052","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/17446651.2018.1434412","article-title":"The effects of hyperprolactinemia and its control on metabolic diseases","volume":"13","author":"Auriemma","year":"2018","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104080_bib0053","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11154-019-09503-1","article-title":"Prolactin and human weight disturbances: a puzzling and neglected association","volume":"20","author":"Sobrinho","year":"2019","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.lpm.2021.104080_bib0054","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/oby.2010.150","article-title":"BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists","volume":"19","author":"dos Santos Silva","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.lpm.2021.104080_bib0055","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000357810","article-title":"Effect of cabergoline on metabolism in prolactinomas","volume":"98","author":"Auriemma","year":"2013","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.lpm.2021.104080_bib0056","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/s12020-013-9931-0","article-title":"Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia","volume":"44","author":"Atmaca","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.lpm.2021.104080_bib0057","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1365-2265.2009.03752.x","article-title":"Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma","volume":"73","author":"Erem","year":"2010","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.lpm.2021.104080_bib0059","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17218199","article-title":"Global prevalence of macroprolactinemia among patients with hyperprolactinemia: a systematic review and meta-analysis","volume":"17","author":"Che Soh","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.lpm.2021.104080_bib0060","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1590\/S0004-27302007000100014","article-title":"[Prevalence of macroprolactinemia among 115 patients with hyperprolactinemia]","volume":"51","author":"Vilar","year":"2007","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.1016\/j.lpm.2021.104080_bib0061","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1210\/jc.2004-2234","article-title":"The impact on clinical practice of routine screening for macroprolactin","volume":"90","author":"Gibney","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104080_bib0062","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.4158\/EP15938.DSC","article-title":"American Association of Clinical Endocrinologists, American College Of Endocrinology Disease State Clinical Review: clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia","volume":"21","author":"Samson","year":"2015","journal-title":"Endocr Pract"},{"key":"10.1016\/j.lpm.2021.104080_bib0063","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF03347299","article-title":"Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect","volume":"21","author":"Petakov","year":"1998","journal-title":"J Endocrinol Investig"},{"key":"10.1016\/j.lpm.2021.104080_bib0064","first-page":"1","article-title":"Prolactinomas and nonfunctioning adenomas: preoperative diagnosis of tumor type using serum prolactin and tumor size","author":"Burke","year":"2019","journal-title":"J Neurosurg"},{"key":"10.1016\/j.lpm.2021.104080_bib0065","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2265.2006.02627.x","article-title":"Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma","volume":"65","author":"Karavitaki","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0066","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/cen.12242","article-title":"Giant prolactinomas: the therapeutic approach","volume":"79","author":"Moraes","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2021.104080_bib0067","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00330-004-2531-x","article-title":"Magnetic resonance imaging of pituitary adenomas","volume":"15","author":"Bonneville","year":"2005","journal-title":"Eur Radiol"},{"key":"10.1016\/j.lpm.2021.104080_bib0068","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s12020-018-1765-3","article-title":"T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists","volume":"63","author":"Burlacu","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.lpm.2021.104080_bib0069","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00234-015-1519-3","article-title":"Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference","volume":"57","author":"Kreutz","year":"2015","journal-title":"Neuroradiology"},{"key":"10.1016\/j.lpm.2021.104080_bib0070","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1210\/jcem-68-2-412","article-title":"The natural history of untreated hyperprolactinemia: a prospective analysis","volume":"68","author":"Schlechte","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104080_bib0071","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11102-020-01039-x","article-title":"Do nothing but observe microprolactinomas: when and how to replace sex hormones?","volume":"23","author":"Bonert","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2021.104080_bib0072","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0015-0282(16)55819-1","article-title":"The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia","volume":"59","author":"Corenblum","year":"1993","journal-title":"Fertil Steril"},{"key":"10.1016\/j.lpm.2021.104080_bib0073","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11102-019-01001-6","article-title":"Magnetic resonance imaging in\u00a0the management of prolactinomas; a review of the evidence","volume":"23","author":"Varlamov","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2021.104080_bib0074","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1210\/jc.2009-2605","article-title":"Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas","volume":"95","author":"Ono","year":"2010","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.lpm.2021.104080_bib0075","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/cen.12149","article-title":"A comparison between intensive and conventional cabergoline treatment of newly diagnosed patients with macroprolactinoma","volume":"79","author":"Rastogi","year":"2013","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0076","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/2046-4053-1-33","article-title":"Treatment of hyperprolactinemia: a systematic review and meta-analysis","volume":"1","author":"Wang","year":"2012","journal-title":"Syst Rev"},{"key":"10.1016\/j.lpm.2021.104080_bib0077","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11011-016-9882-2","article-title":"Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas","volume":"32","author":"Schwetz","year":"2017","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.lpm.2021.104080_bib0078","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0015-0282(16)59548-X","article-title":"Raynaud's phenomenon in infertile women treated with bromocriptine","volume":"48","author":"Quagliarello","year":"1987","journal-title":"Fertil Steril"},{"key":"10.1016\/j.lpm.2021.104080_bib0079","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1016\/j.lpm.2021.104080_bib0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104080_bib0081","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1210\/jc.2007-1403","article-title":"Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline","volume":"93","author":"Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104080_bib0082","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1530\/EJE-13-0231","article-title":"Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas","volume":"169","author":"Auriemma","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0083","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1210\/jc.2009-2095","article-title":"Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia","volume":"95","author":"Valassi","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104080_bib0084","article-title":"A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with Cabergoline","author":"Stiles","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104080_bib0085","article-title":"Incidence of cabergoline associated valvulopathy in primary care patients with prolactinoma using hard cardiac endpoints","author":"Stiles","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104080_bib0086","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/cen.13940","article-title":"Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: A joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology","volume":"90","author":"Steeds","year":"2019","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0087","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/EJE-18-0682","article-title":"Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas","volume":"180","author":"Ioachimescu","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0088","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-18-0667","article-title":"Management of endocrine disease: impulse control disorders in patients with hyperpolactinemia treated with dopamine agonists: how much should we worry?","volume":"179","author":"Barake","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0089","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyt.2011.00001","article-title":"Impulse control disorders: updated review of clinical characteristics and pharmacological management","volume":"2","author":"Schreiber","year":"2011","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.lpm.2021.104080_bib0090","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study","volume":"80","author":"Bancos","year":"2014","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0091","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11102-013-0480-6","article-title":"Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study","volume":"17","author":"Barake","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2021.104080_bib0092","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s12020-018-1744-8","article-title":"Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up","volume":"62","author":"Celik","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.lpm.2021.104080_bib0093","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.579606","article-title":"Depression and impulsivity self-assessment tools to identify dopamine agonist side effects in patients with pituitary adenomas","volume":"11","author":"Hinojosa-Amaya","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0094","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1530\/EJE-16-0897","article-title":"MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment","volume":"176","author":"Eroukhmanoff","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0095","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/jc.2007-0836","article-title":"Long-term management of prolactinomas","volume":"92","author":"Schlechte","year":"2007","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.lpm.2021.104080_bib0096","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia","volume":"349","author":"Colao","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2021.104080_bib0097","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","article-title":"Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis","volume":"95","author":"Dekkers","year":"2010","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.lpm.2021.104080_bib0098","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s11102-014-0617-2","article-title":"Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis","volume":"18","author":"Hu","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2021.104080_bib0099","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","article-title":"Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis","volume":"59","author":"Xia","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.lpm.2021.104080_bib0100","first-page":"105","article-title":"Predictors of the response to dopaminergic therapy in patients with prolactinoma","author":"Hage","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104080_bib0101","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11102-019-00989-1","article-title":"Dopamine agonists in prolactinomas: when to withdraw?","volume":"23","author":"Souteiro","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2021.104080_bib0102","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12020-020-02388-0","article-title":"High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?","volume":"70","author":"Espinosa-C\u00e1rdenas","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.lpm.2021.104080_bib0103","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11060-013-1270-8","article-title":"Management of medically refractory prolactinoma","volume":"117","author":"Molitch","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.lpm.2021.104080_bib0104","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11102-019-00987-3","article-title":"Dopamine agonist resistant prolactinomas: any alternative medical treatment?","volume":"23","author":"Souteiro","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2021.104080_bib0105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"Maiter","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.lpm.2021.104080_bib0106","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1530\/EJE-09-0012","article-title":"Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients","volume":"160","author":"Delgrange","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0107","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-12-0236","article-title":"Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients","volume":"167","author":"Vroonen","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0108","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients","volume":"93","author":"Ono","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104080_bib0109","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EJE-07-0248","article-title":"Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients","volume":"158","author":"Kreutzer","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11102-018-0888-0","article-title":"Management of cystic prolactinomas: a review","volume":"21","author":"Nakhleh","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2021.104080_bib0111","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/EJE-11-1000","article-title":"Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients","volume":"166","author":"Primeau","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0112","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12020-017-1458-3","article-title":"Microsurgical therapy of pituitary adenomas","volume":"59","author":"Mortini","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.lpm.2021.104080_bib0113","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1210\/jc.2003-030461","article-title":"Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume","volume":"88","author":"Barker","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104080_bib0114","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11102-019-01016-z","article-title":"Surgery for prolactinomas: a better choice?","volume":"23","author":"Honegger","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2021.104080_bib0115","first-page":"1","article-title":"The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study","author":"Hung","year":"2019","journal-title":"J Neurosurg"},{"key":"10.1016\/j.lpm.2021.104080_bib0116","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11102-019-00971-x","article-title":"Role of gamma knife radiosurgery in the treatment of prolactinomas","volume":"22","author":"Je\u017ekov\u00e1","year":"2019","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2021.104080_bib0117","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11102-011-0348-6","article-title":"Radiotherapy for prolactin-secreting pituitary tumors","volume":"15","author":"Sheplan Olsen","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2021.104080_bib0118","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.04.003","article-title":"The risk\/benefit ratio of radiotherapy in pituitary tumors","volume":"33","author":"Minniti","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2021.104080_bib0119","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"McCormack","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0120","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11102-019-01000-7","article-title":"Aggressive prolactinomas: how to manage?","volume":"23","author":"Lasolle","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2021.104080_bib0121","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11102-008-0162-y","article-title":"Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma","volume":"14","author":"Fusco","year":"2011","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2021.104080_bib0122","doi-asserted-by":"crossref","first-page":"R213","DOI":"10.1530\/EJE-14-0013","article-title":"Therapy of endocrine disease: the challenges in managing giant prolactinomas","volume":"170","author":"Maiter","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0123","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1055\/a-0752-0741","article-title":"Giant prolactinoma in men: clinical features and therapeutic outcomes","volume":"50","author":"Iglesias","year":"2018","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.lpm.2021.104080_bib0124","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/EJE-13-0503","article-title":"Giant prolactinomas in women","volume":"170","author":"Delgrange","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0125","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/archotol.130.10.1178","article-title":"Diagnostic relevance of beta2-transferrin for the detection of cerebrospinal fluid fistulas","volume":"130","author":"Warnecke","year":"2004","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.lpm.2021.104080_bib0126","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1530\/EJE-10-0651","article-title":"Pituitary apoplexy: re-evaluation of risk factors for bleeding into pituitary adenomas and impact on outcome","volume":"164","author":"M\u00f6ller-Goede","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2021.104080_bib0127","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4158\/EP-2018-0392","article-title":"Management and outcomes of giant prolactinoma: a series of 71 patients","volume":"25","author":"Hamidi","year":"2019","journal-title":"Endocr Pract"},{"key":"10.1016\/j.lpm.2021.104080_bib0128","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ecl.2019.05.004","article-title":"Pituitary tumors in pregnancy","volume":"48","author":"Huang","year":"2019","journal-title":"Endocrinol Metab Clin N Am"},{"key":"10.1016\/j.lpm.2021.104080_bib0129","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11102-019-01010-5","article-title":"Prolactinomas in pregnancy: considerations before conception and during pregnancy","volume":"23","author":"Glezer","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2021.104080_bib0130","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00404-014-3210-z","article-title":"Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database","volume":"290","author":"Hurault-Delarue","year":"2014","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.lpm.2021.104080_bib0131","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11102-019-01008-z","article-title":"A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas","volume":"23","author":"Sant' Anna","year":"2020","journal-title":"Pituitary"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498221000191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498221000191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:07:37Z","timestamp":1760105257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498221000191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":131,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0755498221000191"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2021.104080","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolactinomas","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2021.104080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104080"}}